Lithium use in childhood and adolescence, peripartum, and old age: an umbrella review.

IF 2.8 2区 医学 Q2 PSYCHIATRY
Delfina Janiri, Gaia Sampogna, Umberto Albert, Filippo Caraci, Giovanni Martinotti, Gianluca Serafini, Alfonso Tortorella, Alessandro Zuddas, Andrea Fiorillo, Gabriele Sani
{"title":"Lithium use in childhood and adolescence, peripartum, and old age: an umbrella review.","authors":"Delfina Janiri,&nbsp;Gaia Sampogna,&nbsp;Umberto Albert,&nbsp;Filippo Caraci,&nbsp;Giovanni Martinotti,&nbsp;Gianluca Serafini,&nbsp;Alfonso Tortorella,&nbsp;Alessandro Zuddas,&nbsp;Andrea Fiorillo,&nbsp;Gabriele Sani","doi":"10.1186/s40345-023-00287-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lithium is one of the most consistently effective treatment for mood disorders. However, patients may show a high level of heterogeneity in treatment response across the lifespan. In particular, the benefits of lithium use may vary in special clinical conditions. The aim of this study was to test this hypothesis by conducting an umbrella review on the efficacy and safety of lithium in childhood and adolescence, peripartum and old age.</p><p><strong>Methods: </strong>We applied the Preferred Reporting Items for Systematic Reviews and Meta-analyses criteria (PRISMA) to identify systematic reviews/meta-analyses on the efficacy and/or safety of lithium in mood disorders in special clinical conditions: (i) childhood and adolescence; (ii) peripartum (pregnancy, postpartum and lactation); (iii) old age. The Risk of Bias Assessment Tool for Systematic Reviews (ROBIS) tool was used to assess the risk of bias. Overlap in primary studies across systematic reviews was calculated through the Corrected Covered Area (CCA).</p><p><strong>Results: </strong>We included 20 independent studies, for a total of 8209 individuals treated with lithium. Regarding paediatric age, efficacy and safety results suggested that lithium may be superior to placebo in bipolar disorders (BD) and not associated with serious adverse events. Nevertheless, primary available data are very limited. Efficacy in paediatric major depressive disorder (MDD) is not clear. During peripartum, lithium use was superior to non-lithium in preventing mood episodes and it was associated with low risk of congenital anomalies and with normal child neurodevelopment. Regarding old age, limited evidence supported lithium as an effective treatment in BD and resistant MDD; low doses should be used in this population. Systematic reviews on paediatric age showed the lowest risk of bias (80% of the studies at low risk). The CCA range of included studies was 13-47%.</p><p><strong>Conclusions: </strong>This umbrella review supports the use of lithium across the lifespan, including special clinical condition. Nevertheless, more studies with increased methodological homogeneity are needed.</p>","PeriodicalId":13944,"journal":{"name":"International Journal of Bipolar Disorders","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2023-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925650/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Bipolar Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40345-023-00287-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Lithium is one of the most consistently effective treatment for mood disorders. However, patients may show a high level of heterogeneity in treatment response across the lifespan. In particular, the benefits of lithium use may vary in special clinical conditions. The aim of this study was to test this hypothesis by conducting an umbrella review on the efficacy and safety of lithium in childhood and adolescence, peripartum and old age.

Methods: We applied the Preferred Reporting Items for Systematic Reviews and Meta-analyses criteria (PRISMA) to identify systematic reviews/meta-analyses on the efficacy and/or safety of lithium in mood disorders in special clinical conditions: (i) childhood and adolescence; (ii) peripartum (pregnancy, postpartum and lactation); (iii) old age. The Risk of Bias Assessment Tool for Systematic Reviews (ROBIS) tool was used to assess the risk of bias. Overlap in primary studies across systematic reviews was calculated through the Corrected Covered Area (CCA).

Results: We included 20 independent studies, for a total of 8209 individuals treated with lithium. Regarding paediatric age, efficacy and safety results suggested that lithium may be superior to placebo in bipolar disorders (BD) and not associated with serious adverse events. Nevertheless, primary available data are very limited. Efficacy in paediatric major depressive disorder (MDD) is not clear. During peripartum, lithium use was superior to non-lithium in preventing mood episodes and it was associated with low risk of congenital anomalies and with normal child neurodevelopment. Regarding old age, limited evidence supported lithium as an effective treatment in BD and resistant MDD; low doses should be used in this population. Systematic reviews on paediatric age showed the lowest risk of bias (80% of the studies at low risk). The CCA range of included studies was 13-47%.

Conclusions: This umbrella review supports the use of lithium across the lifespan, including special clinical condition. Nevertheless, more studies with increased methodological homogeneity are needed.

Abstract Image

锂的使用在儿童和青少年,围产期和老年:一个总括的回顾。
背景:锂是治疗情绪障碍最有效的方法之一。然而,患者在整个生命周期中的治疗反应可能表现出高度的异质性。特别是,在特殊的临床条件下,使用锂的益处可能会有所不同。本研究的目的是通过对锂在儿童和青少年、围产期和老年期的有效性和安全性进行综合评价来检验这一假设。方法:我们应用系统评价和荟萃分析标准的首选报告项目(PRISMA)来确定关于锂治疗特殊临床条件下情绪障碍的疗效和/或安全性的系统评价/荟萃分析:(i)儿童和青少年;围产期(怀孕、产后和哺乳期);(iii)老年。采用系统评价偏倚风险评估工具(ROBIS)评估偏倚风险。通过校正覆盖面积(CCA)计算系统评价中主要研究的重叠部分。结果:我们纳入了20项独立研究,共8209例接受锂治疗的个体。关于儿童年龄,疗效和安全性结果表明,锂治疗双相情感障碍(BD)可能优于安慰剂,且与严重不良事件无关。然而,现有的原始数据非常有限。治疗小儿重度抑郁症(MDD)的疗效尚不清楚。在围产期,使用锂在预防情绪发作方面优于不使用锂,并且与先天性异常的低风险和正常的儿童神经发育有关。关于老年,有限的证据支持锂作为BD和耐药MDD的有效治疗;在这一人群中应使用低剂量。对儿童年龄的系统评价显示偏倚风险最低(80%的研究为低风险)。纳入研究的CCA范围为13-47%。结论:该综述支持在整个生命周期中使用锂,包括特殊临床情况。然而,需要更多的研究,增加方法的同质性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Bipolar Disorders
International Journal of Bipolar Disorders Medicine-Psychiatry and Mental Health
CiteScore
6.70
自引率
5.00%
发文量
26
审稿时长
13 weeks
期刊介绍: The International Journal of Bipolar Disorders is a peer-reviewed, open access online journal published under the SpringerOpen brand. It publishes contributions from the broad range of clinical, psychological and biological research in bipolar disorders. It is the official journal of the ECNP-ENBREC (European Network of Bipolar Research Expert Centres ) Bipolar Disorders Network, the International Group for the study of Lithium Treated Patients (IGSLi) and the Deutsche Gesellschaft für Bipolare Störungen (DGBS) and invites clinicians and researchers from around the globe to submit original research papers, short research communications, reviews, guidelines, case reports and letters to the editor that help to enhance understanding of bipolar disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信